Physician profile
Vikas Varma
NPI 1306870720
$11,308.51
in general payments reported to CMS, 2019-2025
43 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.50 · 2020: $1,221 · 2021: $1,267 · 2022: $4,194 · 2023: $1,733 · 2024: $1,658 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,609.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $2,839.38 | 2020-2022 | |
| Abbvie INC. | $1,559.65 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Stryker Corporation | $1,335.97 | 2021-2022 | |
| Pfizer INC. | $815.83 | 2023-2025 | |
| Valinor Pharma, LLC | $554.36 | 2023-2025 | Movantik |
| Alphatec Spine, INC | $505.40 | 2022-2024 | Other - Miscellaneous |
| Boston Scientific Corporation | $399.78 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $381.94 | 2022 | |
| Eisai INC. | $265.26 | 2020-2025 | |
| Nevro Corp. | $246.96 | 2023-2024 | Senza |
| Biohaven Pharmaceuticals, INC. | $210.59 | 2021 | |
| Lundbeck LLC | $189.68 | 2023-2025 | Vyepti, Rexulti |
| Scilex Pharmaceuticals INC. | $178.72 | 2021-2025 | Ztlido |
| Zimvie INC. | $176.94 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $171.97 | 2022-2023 | Seglentis |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $150.98 | 2021-2024 | Austedo Xr |
| Amgen INC. | $147.57 | 2020-2023 | Aimovig |
| Spr Therapeutics, INC | $146.97 | 2023-2024 | Sprint Pns System |
| Axsome Therapeutics, INC. | $88.94 | 2025 | Symbravo |
| Sk Life Science, INC. | $87.51 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $87.15 | 2023-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $75.22 | 2021 | |
| Lilly USA, LLC | $68.88 | 2021-2025 | Kisunla |
| Allergan, INC. | $68.59 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.10 | 2022-2025 | Relistor |
| Abbott Laboratories | $53.50 | 2021 | |
| Bioventus LLC | $47.21 | 2023-2024 | Gelsyn-3, Durolane |
| Medtronic, INC. | $45.00 | 2025 | Pivox Oblique Lateral Spinal System |
| Collegium Pharmaceutical, INC. | $39.55 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $31.71 | 2025 | |
| Spinal Simplicity, LLC | $29.91 | 2025 | Ha Minuteman G3-R |
| Octapharma USA, INC. | $28.60 | 2023 | Panzyga |
| Almatica Pharma LLC | $26.39 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $24.54 | 2023 | Firdapse |
| Cerapedics INC. | $23.78 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Protega Pharmaceutials INC | $22.72 | 2024 | Roxybond |
| Horizon Therapeutics Plc | $21.24 | 2021 | |
| Grt US Holding, INC. | $19.27 | 2021 | |
| Daiichi Sankyo INC. | $17.50 | 2019 | |
| Forte Bio-Pharma LLC | $15.80 | 2023 | Prolate, Nalocet |
| Acadia Pharmaceuticals INC | $15.65 | 2024 | Nuplazid |
| Merck Sharp & Dohme LLC | $14.98 | 2020 | |
| Globus Medical, INC. | $13.82 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Varma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.